Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The management of paranasal sinus and nasal cavity malignancies has evolved significantly with the development of advanced endoscopic techniques and improvements in adjuvant therapy. We sought to characterize both disease-specific survival (DSS) and 5-year conditional disease-specific survival (CDSS, the change in life expectancy with increasing survivorship) for sinus malignancies diagnosed before and after the year 2000.
Methods: Patients diagnosed with sinus and nasal cavity cancer between 1973-2015 were extracted from the Surveillance, Epidemiology, End Results (SEER) registry. Kaplan-Meier analysis for DSS was stratified by year of diagnosis before and after 2000. Cox-proportional hazards models of DSS controlling for stage, age, and year of diagnosis were generated. CDSS was calculated using Cox-regression models stratified by stage.
Results: We analyzed 10,535 patients. Diagnosis after the year 2000 was independently associated with improved DSS (HR:0.81, 95% CI: 0.75-0.87, < .001) after controlling for age and stage. After stratifying by stage, diagnosis after year 2000 was associated with improved DSS for localized (HR:0.71, 0.59-0.86, < .001) malignancies, regional (HR: 0.86, 0.78-0.94, = .001) and distant malignancies (HR 0.74, 0.63-0.87, < .001). CDSS improved with increasing survivorship for all stages of sinus and nasal cavity cancer, and those diagnosed after 2000 had improved CDSS compared to those diagnosed before 2000. Descriptively, the association of year of diagnosis with CDSS diminished with increasing survivorship for localized cancers, but was consistent for other stages.
Conclusion: For paranasal sinus and nasal cavity malignancies, year of diagnosis independently influences both DSS and CDSS. Improved survival is likely due to advances in both surgical and adjuvant treatments. To our knowledge, this study is the first to examine CDSS for these malignancies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/19458924211019158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Collagen proteins, thrombospondin 1 and lumican are differentially expressed across breast cancer subtypes by functional proteomics from core needle biopsy samples of Taiwanese breast cancer.
Biochem Biophys Rep
December 2025
Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, 112, Taiwan.
Purpose: This study aimed to conduct functional proteomics across breast cancer subtypes with bioinformatics analyses.
Methods: Candidate proteins were identified using nanoscale liquid chromatography with tandem mass spectrometry (NanoLC-MS/MS) from core needle biopsy samples of early stage (0-III) breast cancers, followed by external validation with public domain gene-expression datasets (TCGA TARGET GTEx and TCGA BRCA).
Results: Seventeen proteins demonstrated significantly differential expression and protein-protein interaction (PPI) found the strong networks including COL2A1, COL11A1, COL6A1, COL6A2, THBS1 and LUM.
Factors and Disease-Specific Outcomes Associated With Treatment Delays in Osteosarcoma: A Population-Based Retrospective Cohort Study.
J Surg Oncol
September 2025
School of Medicine, Creighton University; Omaha, Nebraska, USA.
Introduction: Time to initiation of therapy in oncological care is an influential factor in disease progression and survival outcomes in many cancer types. We aim to identify factors associated with delayed time to treatment (TTT) in high-grade osteosarcoma and its relationship to disease-specific survival (DSS).
Methods: The SEER database was queried for biopsy-confirmed cases of high-grade osteosarcoma between 2000 and 2021 using ICD-O-3 histology codes 9180/3-9194/3 and primary site codes C40.
Disease-Specific Mortality in Patients With Acromegaly Treated With Pegvisomant: An ACROSTUDY Analysis.
Endocr Connect
September 2025
Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Objective: Characterize disease-specific mortality rates in patients with acromegaly on pegvisomant and identify pertinent risk factors, including on-therapy insulin-like growth factor I (IGF-I) levels.
Design: Retrospective cohort analysis of ACROSTUDY, a global surveillance study of patients with acromegaly receiving pegvisomant.
Methods: Cumulative incidence function to estimate disease-specific mortality and regression analyses to characterize risk factors.
AARS1 Implicates Malignancy and Immune Infiltration in Head and Neck Squamous Cell Carcinoma, Serving as a Prognostic Predictor.
J Oral Pathol Med
September 2025
Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: The aberrant expression of AARS1 has been linked to tumor progression in various cancers. However, its role and underlying mechanisms in head and neck squamous cell carcinoma (HNSCC) remain unclear.
Methods: We validated AARS1 expression using databases and cell lines.
Primary Cutaneous CD4+ Small Medium T Cell Lymphoproliferative Disorder - 20 years of experience from a specialist centre.
Br J Dermatol
September 2025
Clinical Oncology, Guy's and Thomas' NHS Foundation Trust, London, uk.
Background: Primary Cutaneous CD4+ Small Medium T Cell Lymphoproliferative Disorder (PCSM-TLPD) is a rare subtype of indolent lymphoproliferative disease. The treatment, investigations and follow-up protocol are being re-evaluated.
Objective: To use our service evaluation to understand the presentation, response rate, relapse rate, treatment variation, progression free and overall survival of our cohort.